Schrödinger: An Interesting Investment With Immense Potential
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Dawn12h
Kalbe Ali
PTI founder pens 2nd open letter to army chief; claims his convictions were predetermined; criticises Peca for restricting social media. Updated 10 Feb, 2025 02:34am ...